Format
Sort by
Items per page

Send to

Choose Destination

Best matches for DESVENLAFAXINE/PD:

Search results

Items: 1 to 20 of 37

1.

Withdrawal-Emergent Dyskinesia Following Abrupt Discontinuation of Desvenlafaxine.

Wu L, Gerdts EA, Alam A.

Prim Care Companion CNS Disord. 2019 Jan 10;21(1). pii: 18l02362. doi: 10.4088/PCC.18l02362. No abstract available.

2.

Cognitive Deficits Following a Post-Myocardial Infarct in the Rat Are Blocked by the Serotonin-Norepinephrine Reuptake Inhibitor Desvenlafaxine.

Malick M, Gilbert K, Brouillette J, Godbout R, Rousseau G.

Int J Mol Sci. 2018 Nov 26;19(12). pii: E3748. doi: 10.3390/ijms19123748.

3.

Switch to a manic episode after desvenlafaxine discontinuation in bipolar disorder.

Muquebil Ali Al Shaban-Rodríguez OW, Álvarez de Morales E, Rodríguez-Turiel C, Fernández-Menéndez MA, García-Álvarez G.

Actas Esp Psiquiatr. 2018 Jul;46(4):156-8. Epub 2018 Jul 1. No abstract available.

4.

Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review.

Fava GA, Benasi G, Lucente M, Offidani E, Cosci F, Guidi J.

Psychother Psychosom. 2018;87(4):195-203. doi: 10.1159/000491524. Epub 2018 Jul 17. Review.

5.

Evaluation of the Effects of Apatinib on the Pharmacokinetics of Venlafaxine and O-desmethylvenlafaxine in SD Male Rats by UPLC-MS/MS.

Bao SS, Wen J, Lin QM, Li YH, Huang YG, Zhou HY, Hu GX.

Basic Clin Pharmacol Toxicol. 2018 Dec;123(6):721-726. doi: 10.1111/bcpt.13081. Epub 2018 Aug 2.

PMID:
29964362
6.

Population Pharmacokinetics of Desvenlafaxine: Pharmacokinetics in Korean Versus US Populations.

Nichols AI, Liao S, Abbas R.

Clin Pharmacol Drug Dev. 2018 May;7(4):441-450. doi: 10.1002/cpdd.419. Epub 2017 Dec 11.

PMID:
29228473
7.

An open-label positron emission tomography study to evaluate serotonin transporter occupancy following escalating dosing regimens of (R)-(-)-O-desmethylvenlafaxine and racemic O-desmethylvenlafaxine.

Frankle WG, Robertson B, Maier G, Paris J, Asmonga D, May M, Himes ML, Mason NS, Mathis CA, Narendran R.

Synapse. 2018 Mar;72(3). doi: 10.1002/syn.22021. Epub 2017 Dec 13.

PMID:
29216407
8.

Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder.

Weihs KL, Murphy W, Abbas R, Chiles D, England RD, Ramaker S, Wajsbrot DB.

J Child Adolesc Psychopharmacol. 2018 Feb;28(1):36-46. doi: 10.1089/cap.2017.0100. Epub 2017 Nov 30.

9.

Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder.

Atkinson S, Lubaczewski S, Ramaker S, England RD, Wajsbrot DB, Abbas R, Findling RL.

J Child Adolesc Psychopharmacol. 2018 Feb;28(1):55-65. doi: 10.1089/cap.2017.0099. Epub 2017 Nov 29.

10.

False-positive phencyclidine (PCP) on urine drug screen attributed to desvenlafaxine (Pristiq) use.

Farley TM, Anderson EN, Feller JN.

BMJ Case Rep. 2017 Nov 23;2017. pii: bcr-2017-222106. doi: 10.1136/bcr-2017-222106.

PMID:
29170178
11.

Antidepressant polypharmacy and the potential of pharmacokinetic interactions: Doxepin but not mirtazapine causes clinically relevant changes in venlafaxine metabolism.

Paulzen M, Haen E, Hiemke C, Fay B, Unholzer S, Gründer G, Schoretsanitis G.

J Affect Disord. 2018 Feb;227:506-511. doi: 10.1016/j.jad.2017.11.046. Epub 2017 Nov 13.

PMID:
29156365
12.

Takotsubo Cardiomyopathy and Intraoperative Cardiac Arrest: Is Desvenlafaxine a Contributing Factor?

Gurunathan U.

J Cardiothorac Vasc Anesth. 2018 Feb;32(1):e16-e18. doi: 10.1053/j.jvca.2017.08.031. Epub 2017 Aug 19. No abstract available.

PMID:
29153932
13.
14.

Efficacy of Desvenlafaxine Compared With Placebo in Major Depressive Disorder Patients by Age Group and Severity of Depression at Baseline.

Mosca D, Zhang M, Prieto R, Boucher M.

J Clin Psychopharmacol. 2017 Apr;37(2):182-192. doi: 10.1097/JCP.0000000000000674.

PMID:
28146000
15.
16.

Desvenlafaxine overdose and the occurrence of serotonin toxicity, seizures and cardiovascular effects.

Cooper JM, Brown JA, Cairns R, Isbister GK.

Clin Toxicol (Phila). 2017 Jan;55(1):18-24. doi: 10.1080/15563650.2016.1223847. Epub 2016 Sep 13.

PMID:
27622824
17.

Pharmacokinetics and Tolerability of Single-Ascending Doses of Desvenlafaxine Administered to Children and Adolescents with Major Depressive Disorder.

Findling RL, Groark J, Tourian KA, Ramaker SA, Chiles D, Yang L, Nichols AI.

J Child Adolesc Psychopharmacol. 2016 Dec;26(10):909-921. Epub 2016 Jul 18.

PMID:
27428303
18.
19.

The effects of desvenlafaxine on neurocognitive and work functioning in employed outpatients with major depressive disorder.

Lam RW, Iverson GL, Evans VC, Yatham LN, Stewart K, Tam EM, Axler A, Woo C.

J Affect Disord. 2016 Oct;203:55-61. doi: 10.1016/j.jad.2016.05.074. Epub 2016 May 31.

PMID:
27280963
20.

Clinical Experience With Desvenlafaxine in Treatment of Patients With Fibromyalgia Syndrome.

Allen R, Sharma U, Barlas S.

Clin Pharmacol Drug Dev. 2017 May;6(3):224-233. doi: 10.1002/cpdd.271. Epub 2017 Feb 17.

PMID:
27139158

Supplemental Content

Loading ...
Support Center